Growth Arrest-Specific 6 and Cardiometabolic Risk Factors in Patients with Psoriasis


SÜNBÜL M., Cagman Z. , Gerin F., ÖZGEN Z., Durmus E., Seckin D., et al.

CARDIOVASCULAR THERAPEUTICS, cilt.33, ss.56-61, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 33 Konu: 2
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1111/1755-5922.12112
  • Dergi Adı: CARDIOVASCULAR THERAPEUTICS
  • Sayfa Sayısı: ss.56-61

Özet

ObjectivesAn increased risk for cardiovascular disease with psoriasis has been reported. Growth Arrest-Specific 6 (GAS6) amplifies pro-inflammatory endothelial cell activation via TAM receptors. However, it also inhibits inflammation by multiple mechanisms including phagocytosis. The objective of this study was to investigate whether plasma GAS6 levels are associated with conventional cardiometabolic (CM) risk factors in patients with psoriasis.